GlassScriptPhysician profile
Michael J Cloy
NPI 1447230263
$1,923.34
in general payments reported to CMS, 2019-2025
33 companies · $662 in 2025
The $662 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $164 · 2023: $441 · 2024: $313 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.84 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.51 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $211.80 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $205.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $168.94 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $164.88 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $111.11 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $96.72 | 2023-2025 | Givlaari |
| Janssen Pharmaceuticals, INC | $74.07 | 2021-2024 | Xarelto |
| Smith+Nephew, INC. | $69.01 | 2024 | |
| Abbott Laboratories | $57.83 | 2021-2025 | Freestyle Insulinx, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $49.35 | 2024-2025 | |
| Exact Sciences Corporation | $47.95 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $47.75 | 2023-2024 | Repatha, Otezla |
| Gilead Sciences, INC. | $36.44 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $30.57 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.10 | 2025 | Voquezna |
| Genzyme Corporation | $26.13 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.30 | 2025 | Eliquis |
| Merck Sharp & Dohme LLC | $24.90 | 2021-2022 | |
| Organon LLC | $21.49 | 2021-2024 | |
| Dexcom, INC. | $18.42 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $17.75 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $16.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.28 | 2024 | Caplyta |
| Corcept Therapeutics | $16.13 | 2023 | Korlym |
| Medtronic, INC. | $14.54 | 2021 | |
| Halozyme INC | $14.47 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.48 | 2023 | Austedo Xr |
| Astellas Pharma US INC | $13.39 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $12.50 | 2022 | |
| Genentech USA, INC. | $5.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cloy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.